Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.

Serum Homocysteine Level in Acne Patients Before and After Oral Isotretinoin

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05529888

Enrollment

Registered

2022-09-07

Start date

2020-12-15

Completion date

2021-12-15

Last updated

2022-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

Serum homocysteine level in Acne patients before and after oral Isotretinoin and Correlation between serum level of homocysteine in acne patients before and after Oral isotretinoin treatment

Detailed description

Acne vulgaris is a common chronic inflammatory disease of the skin. It is found in about 80% of young adults and adolescents. It is a disease that affects the pilosebaceous units of the skin and may result in inflammatory or non-inflammatory lesions,Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne The standard dose of isotretinoin is 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120-140 mg/kg is effective in the management of acne vulgaris The scope of our study is to detect serum homocysteine level in acne patient befor and after oral isotrtinoin treatment

Interventions

DRUGIsotretinoin

Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

group of patients and group of control

Eligibility

Sex/Gender

ALL

Age

15 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Patients of both sexes with acne vulgaris

Exclusion criteria

* Patients with history of malignancies. * Patients with renal and hepatic dysfunction. * Cardiac patient. * Pregnant, lactating and female welling to have pregnancy in the period of study. * Patient with absorption disorder. * Patient with history of favism. * Patient has already been treated with isotretinoin.

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the effect of oral isotretinoin on Serum homocysteine in acne vulgaris patients	3 months	Assessment in serum level homocysteine level in acne vulgaris patients after isotretinoin therapy with assesment of its level before starting therapy for detecting changes in serum homocysteine and effect of isotretinoin therapy on it.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026